Insights
Search Results
Client Highlights
1.28.26
Wilson Sonsini Advises Boyu Capital on $110 Million Convertible Bond Investment in Gushengtang
On January 26, 2026, Gushengtang Holdings Limited (Gushengtang) announced that it had entered into a subscription agreement with an investment vehicle of Boyu Capital for the issuance and subscription of convertible bonds of Gushengtang in the aggregate principal amount of $110 million.
Client Highlights
10.28.25
Wilson Sonsini Advises WuXi AppTec on Sale of China-Based Clinical Research Services Business to Hillhouse
On October 24, 2025, WuXi AppTec Co., Ltd. (WuXi AppTec), a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that its wholly owned subsidiary has entered into a sale and purchase agreement to sell its two subsidiaries, WuXi Clinical Development Services (Shanghai) Co., Ltd. (WuXi Clinical) and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. (WuXi MedKey), to Hillhouse Investment Management (Hillhouse), one of the world’s leading global private asset managers focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology. WuXi Clinical and WuXi MedKey are the operating entities of WuXi AppTec engaged in China-based clinical research services.
Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction. The Wilson Sonsini team includes:
Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction. The Wilson Sonsini team includes:
Client Highlights
3.04.25
Wilson Sonsini Advises WuXi AppTec on Sale of U.S. Medical Device Testing Operations to NAMSA
On March 3, 2025, WuXi AppTec announced that it had completed the sale of its U.S. medical device testing operations to NAMSA. Wilson Sonsini is pleased to have represented WuXi AppTec throughout this transaction.
Client Highlights
1.21.25
Wilson Sonsini Advises WuXi AppTec on Sale of Its U.S. Medical Device Testing Operations to NAMSA
On January 17, 2025, WuXi AppTec, a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has entered into a definitive agreement to sell its U.S. medical device testing operations to NAMSA, a Toledo, Ohio-based MedTech testing, clinical, and regulatory consulting firm. Under the agreement, NAMSA will acquire WuXi AppTec’s medical device testing facilities in Minnesota and Georgia. Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction.
Client Highlights
6.10.24
Firm Advises Plutonian Acquisition Corp. on De-SPAC Transaction with Big Tree Cloud International Group Limited
On June 6, 2024, Plutonian Acquisition Corp. (Plutonian) completed its initial business combination with Big Tree Cloud International Group Limited (Big Tree Cloud). On June 7, 2024, the latter began trading its shares and warrants on the Nasdaq Stock Market under the symbols “DSY” and “DSYW,” respectively.
Plutonian is a Delaware corporation incorporated as a blank check company, or special purpose acquisition company (SPAC), for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. Big Tree Cloud is a company devoted to the development, production, and sales of personal care products and other consumer goods in China.
Plutonian is a Delaware corporation incorporated as a blank check company, or special purpose acquisition company (SPAC), for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. Big Tree Cloud is a company devoted to the development, production, and sales of personal care products and other consumer goods in China.
Client Highlights
4.17.24
Firm Advises Investors on D3 Bio’s $62 Million Series A+ Financing
On April 8, 2024, D3 Bio, Inc., a globally orientated, clinical-stage biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology, announced its closing of a $62 million Series A+ financing. The financing was led by Medicxi, a leading European life sciences investment firm, with participation by existing investors Matrix Partners China and WuXi AppTec’s corporate venture fund. The funding will be allocated to expedite the development of D3 Bio’s assets through preclinical and clinical stages, with a particular focus on accelerating the global clinical trial of D3S-001, a new generation small molecule KRAS G12C inhibitor with the best-in-class potential. D3S-001 is currently in Phase II development in non-small cell lung cancer, colorectal cancer, and pancreatic cancer.
Wilson Sonsini advised existing investors, including Matrix Partners China and WuXi AppTec’s corporate venture fund, on this transaction. The Wilson Sonsini team was led by partner Jie Zhu, and included Jill Sheng, Xuchao Dong, and Yang Liao.
Wilson Sonsini advised existing investors, including Matrix Partners China and WuXi AppTec’s corporate venture fund, on this transaction. The Wilson Sonsini team was led by partner Jie Zhu, and included Jill Sheng, Xuchao Dong, and Yang Liao.
Client Highlights
4.03.24
Cayman Court of Appeal Dismisses Appeal Against Interim Quia Timet Injunction Granted Pursuant to Section 54 of Arbitration Act
The Court of Appeal of the Cayman Islands Reaffirms Ruling of the Grand Court of the Cayman Islands and Provides Further Guidance on the Interpretation of Section 54 of the Arbitration Act
Client Highlights
10.16.23
Wilson Sonsini Advises Plutonian Acquisition Corp. on Merger with Big Tree Cloud
On October 9, 2023, Big Tree Cloud International Group Limited (Big Tree Cloud), a company devoted to the development, production, and sales of personal care products and other consumer goods in China, and Plutonian Acquisition Corp. (Plutonian), a Nasdaq-listed special purpose acquisition company, announced that they have entered into a definitive agreement for a business combination between Big Tree Cloud and Plutonian. Upon the completion of the business combination, the combined company will become a publicly traded company on the Nasdaq Stock Market. The business combination reflects an initial equity value of approximately US$500 million for Big Tree Cloud.
Client Highlights
8.02.23
Wilson Sonsini Advises Boyu Capital on Quasar Medical Acquisition
On July 31, 2023, The Longreach Group announced that it had, together with the founder family minority shareholders, completed the sale of all the issued and outstanding shares in Quasar Medical to funds managed by Boyu Capital. The deal value was not disclosed. Wilson Sonsini Goodrich & Rosati represented Boyu Capital in this acquisition.
Client Highlights
7.24.23
Wilson Sonsini Advises Michael Li on Harris Ownership Group’s $6.05B Acquisition of the Washington Commanders
On July 21, 2023, a partnership led by Josh Harris announced the closing of its $6.05 billion acquisition of the Washington Commanders pursuant to the sale and purchase agreement entered into on May 12, 2023. The Harris group’s ownership was approved by the NFL at a league meeting on July 20, 2023.
Client Highlights
3.27.23
Wilson Sonsini Represents Aquaron Acquisition Corp. on Merger with Bestpath
On March 27, 2023, Bestpath (Shanghai) IoT Technology Co., Ltd. (Bestpath), a pioneering hydrogen fuel cell powered vehicle company in China, and Aquaron Acquisition Corp. (Aquaron), a Nasdaq listed special purpose acquisition company, announced that they have entered into a definitive agreement for a business combination between Bestpath and Aquaron. Upon completion of the business combination, the company will become a publicly traded company on the Nasdaq Stock Market. Wilson Sonsini Goodrich & Rosati represented Aquaron in this transaction. The business combination reflects an initial equity value of approximately US$1.2 billion for Bestpath.